A highly specific, synthetic peptide vascular endothelial growth factor receptor-2 (VEGFR-2) antagonist with potential antiangiogenic activity. Derived from human fibronectin with a proprietary protein engineering process, VEGFR-2 inhibitor peptide CT-322 may block the activation of VEGFR-2 by all known activating ligands, thereby inhibiting the growth of new tumor blood vessels.